Shionogi Salute del bilancio

Salute finanziaria criteri di controllo 0/6

Informazioni chiave

Rapporto debito/patrimonio netto

JP¥0

Debito

Indice di copertura degli interessi	-3.4x
Contanti	JP¥303.41b
Patrimonio netto	JP¥1.31t
Totale passività	JP¥145.93b
Totale attività	JP¥1.46t

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Shionogi Salute del bilancio

Salute finanziaria criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Shionogi & Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025

Shionogi & Co., Ltd. Announces Dividend for the Second Quarter of Year Ending March 31,2025, Payable on December 2,2024; Provides Dividend Guidance for the Full Year Ending March 31,2025

Shionogi & Co., Ltd. Announces Presents Global Real-World Evidence Study of Cefiderocol Demonstrating Strong Clinical Response Rates Across Seriously III Patients

Shionogi & Co., Ltd. Submits New Drug Application in Japan for Zuranolone as A Treatment for Major Depressive Disorder

Shionogi & Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2025

Shionogi & Co., Ltd. to Report Q2, 2025 Results on Oct 28, 2024

Shionogi & Co., Ltd. to Report Q1, 2025 Results on Jul 29, 2024

Shionogi & Co., Ltd., Annual General Meeting, Jun 20, 2024

Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024

Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study (PERSEUS) of Fetroja®/F etcroja® (cefiderocol)

Shionogi & Co., Ltd. to Report Fiscal Year 2024 Results on May 13, 2024

Akili, Inc. Announces Positive Results from Shionogi & Co., Ltd. Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx for Pediatric ADHD Patients in Japan

Shionogi & Co., Ltd. Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open

Shionogi & Co., Ltd Announces the Launch of Fetroja(Cefiderocol) Intravenous Infusion 1g Vial in Japan on December 20, 2023

Shionogi & Co., Ltd. Initiation of a Phase 3 Additional Dose Clinical Trial in Japanese Subjects of the Monovalent Vaccine for the XBB1.5 Strain, S-268023

Shionogi & Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

Shionogi & Co., Ltd. Presents New Real-World Evidence Demonstrating Effectiveness of Early Treatment with Fetroja®? (Cefiderocol) in Appropriate Patients

Shionogi & Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023

Shionogi & Co., Ltd. (TSE:4507) announces an Equity Buyback for 12,500,000 shares, representing 4.2% for ¥7,500 million.

Eddingpharm Announces Approval of Mulpleta®? (Lusutrombopag) in China

Shionogi & Co., Ltd. Announces Initiation of a Phase 3 Clinical Trial in Japanese Pediatric Patients of Ensitrelvir for COVID-19

Shionogi & Co., Ltd. Enrolls the First Participant in Japan in its Global Phase 3 Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection

Shionogi & Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Shionogi & Co., Ltd. Announces Year-End Dividend for the Year Ended March 31, 2023, Payable on June 22, 2023; Provides Dividend Guidance for the End of Second Quarter of Fiscal Year 2024

Shionogi & Co., Ltd., Annual General Meeting, Jun 21, 2023

Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program

Shionogi & Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Shionogi & Co., Ltd. Announces Availability of Innovative Antibiotic, Cefiderocol in Norway

Shionogi & Co., Ltd. Announces Initiation of Phase1/2/3 Clinical Trial (Part 2), Phase 3 Additional Dose Clinical Trial in Japanese Pediatric of the COVID-19 Vaccine, S-268019

Shionogi & Co., Ltd. to Report Q3, 2023 Results on Jan 30, 2023

Shionogi & Co., Ltd. Files for Approval of S-268019, A COVID-19 Recombinant Protein-Based Vaccine, in Japan

Shionogi & Co., Ltd. Announces Tablets 125Mg Approved in Japan for the Treatment of SARS-CoV-2 Infection

Shionogi & Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2022, Payable on December 1, 2022

Shionogi & Co., Ltd. Revises Consolidated Earnings Guidance for First Half of the Fiscal Year Ending March 31, 2023

Shionogi & Co., Ltd. Announces Achievement of the Primary Endpoint for Ensitrelvir (S-217622) in the Phase 3 part of the Phase 2/3 Clinical Trial in Asia

Shionogi & Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

Shionogi & Co., Ltd Announces Ensitrelvir Fumaric Acid (S-217622), Therapeutic Drug for COVID-19,Shows High In Vitro Antiviral Activity Against Omicron Subvariants BA.2.75

Shionogi & Co., Ltd. Provides Year-End Dividend Guidance for the Year Ending March 31, 2023

Shionogi & Co., Ltd. Initiates Fourth Vaccination Trail

Shionogi & Co., Ltd. Announces Initiation of A Clinical Trial in Japanese Pediatric Subjects of the COVID-19 Recombinant Protein-Based Vaccine, S-268019

Shionogi & Co., Ltd. Announces S-217622, A Therapeutic Drug for Covid-19, Shows High in Vitro Antiviral Activity Against Omicron Subvariants BA.4 and BA.5

Shionogi & Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Shionogi Announces Appointment of Corporate Officers, Corporate Reorganization and Personnel Reassignment

Shionogi Announces Appointment of Corporate Officers, Corporate Reorganization and Personnel Reassignment

Shionogi & Co. Announces Initiation of a Phase 2/3 Clinical Trial in Japanese Adolescents for the Covid-19 Recombinant Protein-Based Vaccine, S-268019

Shionogi & Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2022 and Full Year Ending March 31, 2023

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane